Symptomatic Treatment in Multiple Sclerosis

Sandra Bigi¹ and E Ann Yeh²

1. Clinical Research Fellow, MS and Demyelinating Disorders Program, Hospital for Sick Children, University of Toronto, Ontario, Canada; 2. Associate Professor of Pediatrics (Neurology), University of Toronto; Director, Pediatric MS and Demyelinating Disorders Program, Director, Pediatric Neurology Training Program, Associate Scientist, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada

Citation: European Neurological Review, 2014;9(2):xii[online only]

In order to comply with the latest recommendations outlined by ICMJE the publisher would like to make the following amendments to the Disclosure section of the above-mentioned paper: No funding was received for the publication of this article.